热门资讯> 正文
Genprex与NYU Langone Health达成专利许可协议
2025-04-28 19:43
- Genprex (NASDAQ:GNPX) said it has signed an exclusive patent license agreement with NYU Langone Health related to the drug candidate, Reqorsa Gene Therapy.
- The firm added that the therapy is under investigation as a potential treatment for mesothelioma.
- The subject patent is co-owned by Genprex and NYU Langone Health, and the license provides Genprex with patent exclusivity.
More on Genprex
- Seeking Alpha’s Quant Rating on Genprex
- Financial information for Genprex
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。